NASDAQ$SGMT

Sagimet Biosciences Inc-A · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Headline financials

EPS (adj)

$6.69K

No prior period
Net Income

-$7.47M

No prior period
Operating Income

-$7.69M

No prior period
Cash & Equivalents

$2.23M

No prior period
Stock-Based Comp

$389K

No prior period

Revenue & EPS history

Sagimet Biosciences · Revenue · Quarterly

$0

Q4 2026

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 10 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

-3.0%

Avg return

Earnings day

+0.6%

Avg return

5 days after

+17.0%

Avg return

30 days after

43%

6 / 14 earnings

Positive

+16.0%

Q4 2023

Best reaction

-21.4%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026-0.2%-10.2%-16.5%
Q3 2025-12.5%-11.3%-29.4%
Q1 2025+6.6%+7.1%+118.6%
Q4 2024+3.5%-7.0%-30.5%
Q3 2024-21.4%-26.7%-27.1%
Q2 2024+3.8%+6.0%+39.8%
Q1 2024+8.4%+8.2%-5.5%
Q1 2023+8.4%+8.2%-5.5%
Q4 2023+16.0%+20.2%-7.5%
Q3 2022-2.5%+14.5%+113.9%
Q3 2023-2.5%+14.5%+113.9%
Q2 2022-16.3%-5.1%-8.6%
Q2 2023-16.3%-5.1%-8.6%
Q4 2022-16.3%-5.1%-8.6%
Q1 2022
Q1 2021
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro